Xeljanz xr and Bladder cancer - a phase IV clinical study of FDA data

Summary:

Bladder cancer is reported as a side effect among people who take Xeljanz xr (tofacitinib citrate), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Humalog, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Bladder cancer when taking Xeljanz xr. It is created by eHealthMe based on reports of 106,412 people who have side effects when taking Xeljanz xr from the FDA, and is updated regularly.

What is Xeljanz xr?

Xeljanz xr has active ingredients of tofacitinib citrate. eHealthMe is studying from 106,446 Xeljanz xr users. Check the latest studies of Xeljanz xr.

What is Bladder cancer?

Bladder cancer is found to be associated with 727 drugs and 1,027 conditions by eHealthMe. Check the latest studies of Bladder cancer.

On Jul, 21, 2026

106,412 people reported to have side effects when taking Xeljanz xr.
Among them, 22 people (0.02%) have Bladder cancer.

Among these 22 people:

How long have people been on Xeljanz xr when they have Bladder cancer? *

What is the gender of people who have Bladder cancer when taking Xeljanz xr? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Bladder cancer when taking Xeljanz xr? *

What are other drugs people take besides Xeljanz xr? *

Cosentyx: 2 people, 9.09%
Vitamin B12: 2 people, 9.09%
Onglyza: 2 people, 9.09%
Humalog: 2 people, 9.09%
Xeljanz: 1 person, 4.55%
Losartan Potassium: 1 person, 4.55%
Enbrel: 1 person, 4.55%
Famotidine: 1 person, 4.55%
Glimepiride: 1 person, 4.55%
Imipramine Hydrochloride: 1 person, 4.55%

What are other side effects people have besides Bladder cancer? *

Pain: 3 people, 13.64%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 13.64%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 2 people, 9.09%
Nausea And Vomiting: 2 people, 9.09%
Cardiac Failure: 2 people, 9.09%
Diarrhea: 2 people, 9.09%
Feeling Abnormal: 2 people, 9.09%
Fever: 2 people, 9.09%
Haematuria (presence of blood in urine): 2 people, 9.09%
Heart Attack: 2 people, 9.09%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 12 people, 54.55%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 13.64%
Rheumatoid Factor Positive: 1 person, 4.55%
High Blood Cholesterol: 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz xr and have Bladder cancer?

- Check whether Bladder cancer is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeljanz xr:

Xeljanz xr (106,446 reports)

Bladder cancer treatments and more:

Bladder cancer (75,593 reports)

Browse all side effects of Xeljanz xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bladder cancer:

Bladder cancer (727 drugs)

Browse all the conditions that are associated with Bladder cancer:

Bladder cancer (1,027 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz xr) and Xeljanz xr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.